Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1843 • ACR Convergence 2025
Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Norio Hanata¹, Carmelo Carmona-Rivera¹, Victoria Hoffman², Kan Jiang³, davide Randazzo⁴, Meryl Waldman⁵, Sarfaraz Hasni⁶ and Mariana Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ³Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Bethesda, PA, ⁶National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease that frequently affects the kidneys, with lupus nephritis (LN) being a major contributor to morbidity…
Abstract Number: 1771 • ACR Convergence 2025
Interferon- α, Anti-Interferon-Alpha Antibodies and Disease Activity in Systemic Lupus Erythematosus
Gollakota Nandita¹, Kambhampati Sreelekha², Kaushik Puranam³, Phani Kumar D⁴, Meghna Gavali⁵ and Liza rajasekhar⁶, ¹NIMS, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, ⁴NIMS, Hyderabad, Telangana, India, ⁵nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ⁶Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease, partly driven by Interferon-alpha (IFN-α). Studies suggest that anti-IFN-α antibodies (AIAA) may neutralize IFN-α, potentially…
Abstract Number: 1700 • ACR Convergence 2025
Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions
Mikhail Olferiev¹, Kyriakos Kirou¹, Emily Wu², Dina Greenman¹ and Mary Crow³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Union City, NJ, ³Hospital for Special Surgery, New York
Background/Purpose: SLE occurs more frequently in females than males, with relative prevalence 9-10:1. While the impact of hormones on immune function may contribute to the…
Abstract Number: 1575 • ACR Convergence 2025
Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Kevin Chevalier¹, Brigitte Bader-Meunier², Isabelle Kone-Paut³, Benjamin Torreau⁴, Marc Michel⁵, Bertrand Godeau⁵, Christian AGARD⁶, Thomas Papo⁷, Karim Sacré⁸, Raphaele Seror⁹, Xavier Mariette¹⁰, Cacoub Patrice¹¹, Ygal Benhamou¹², Mathilde Leclercq¹³, Cécile goujard¹⁴, Olivier Lambotte³, Bernard Bonnotte¹⁵, Maxime Samson¹⁶, Félix Ackermann¹⁷, Jean Schmidt¹⁸, Pierre Duhaut¹⁸, Jean-Emmanuel Kahn¹⁹, Thomas Hanslik¹⁹, Nathalie Costedoat-Chalumeau²⁰, Benjamin Terrier²⁰, Alexis REGENT²¹, bertrand Dunogue²², Pascal Cohen²³, Véronique Le Guern²⁰, Eric HACHULLA²⁴, Luc Mouthon²² and Benjamin Chaigne²², ¹Université Paris Cité, Montrouge, France, ²Necker hospital, Paris, France, ³Bicêtre hospital, Kremlin Bicêtre, France, ⁴Internal Medicine and Immunology, CHU Tours, Tours, France, ⁵Henri Mondor hospital, Créteil, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷Bichat hospital, Paris, France, ⁸Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ¹¹Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹²Internal Medicine, CHU Rouen, Rouen, France, ¹³Rouen hospital, Rouen, France, ¹⁴Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹⁵Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Foch hospital, Suresnes, France, ¹⁸Amiens hospital, Amiens, France, ¹⁹Ambroise Paré hospital, Boulogne, France, ²⁰Cochin hospital, Paris, France, ²¹Hopital Cochin, Paris, France, ²²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France
Background/Purpose: Mixed connective tissue disease (MCTD) is an entity defined by clinical features of differentiated connective tissue diseases (dCTD), such as systemic lupus erythematosus (SLE),…
Abstract Number: 1535 • ACR Convergence 2025
INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases
Lei Ding, Yanjie Li, Mariska ter Haak, Sadhak Sengupta, Kate Rochlin and Lawrence Lamb, IN⁸bio, Inc., New York, NY
Background/Purpose: T cell engagers (TCEs) redirect T cells to bind target cells by linking T cells with target-associated antigens expressed on cells responsible for disease…
Abstract Number: 1516 • ACR Convergence 2025
The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
Jennifer Lee¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) affects over 50% of SLE patients. Twenty percent of LN patients develop end-stage renal disease (ESRD) within 10 years. The 2021…
Abstract Number: 1493 • ACR Convergence 2025
Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
Lilliana Serrano-Arroyo, César Rosado-Bloise and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: The post-acute sequelae of SARS-CoV-2 infection may involve low-grade inflammation, immune dysregulation, and endothelial dysfunction. Therefore, it would not be surprising if SARS-CoV-2 negatively…
Abstract Number: 1476 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
Bana Shawareb¹, Muhannad Haddadin¹, Ansaam Daoud² and Omer Pamuk³, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread immune dysregulation and multi-organ involvement. Autoimmune hemolytic anemia (AIHA), marked by antibody-mediated…
Abstract Number: 1293 • ACR Convergence 2025
Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study
Marianna Freire¹, Jean Paulo Veronese de Souza¹, Ana Renata Oliveira¹, Renata Kobayasi², Vitor Paula³, Clovis Artur Silva⁴ and Lucia Maria Campos⁵, ¹Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, ²Centro de Desenvolvimento de Educação Médica do Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, ³Pediatric Radiology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, ⁴University of São Paulo, São Paulo, São Paulo, Brazil, ⁵Instituto da Criança e do Adolescente, São Paulo, São Paulo, Brazil
Background/Purpose: Musculoskeletal (MSK) involvement occurs in up to 70% of childhood-onset systemic lupus erythematosus (cSLE). MSK ultrasound (US) has emerged as a tool with greater…
Abstract Number: 1223 • ACR Convergence 2025
Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Alexis Ogdie¹, Astrid Rasmussen², Dana Orange³, Michelle Petri⁴, Caroline Shiboski⁵, Rebecca Haberman⁶, Mala Masson⁷, Daniel Goldman⁴, Peter Izmirly⁸, Brooke Cohen⁹, Jennifer Seifert¹⁰, Jennifer Anolik¹¹, Wade DeJager¹², Alan Baer¹³, Jill Buyon¹⁴ and Yvonne Lee¹⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³The Rockefeller University, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸New York University Grossman School of Medicine, New York, NY, ⁹Yale Physician Associate Program, New Haven, CT, ¹⁰University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ¹¹University of Rochester Medical Center, Rochester, NY, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵Northwestern University, Chicago, IL
Background/Purpose: The Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) network seeks to understand the cellular and molecular interactions that lead to inflammation and…
Abstract Number: 1029 • ACR Convergence 2025
Cervical cancer screening rates in Korean women of childbearing age with systemic lupus erythematosus
PIL GYU PARK¹, Jisoo Lee², JIN SU PARK³, Hyunsun Lim³, In-Woon Baek⁴, Min Kyung Chung⁴ and Chan Hee Lee⁵, ¹National Health Insurance Service Ilsan Hospital, Seodaemun-gu, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Ewha Womans University College of Medicine, SEOUL, Republic of Korea, ³National Health Insurance Service Ilsan Hospital, Goyang-si, Republic of Korea, ⁴Ewha Womans University College of Medicine, Seoul, Republic of Korea, ⁵Desert Regional Medical Center, Palm Springs, CA
Background/Purpose: Cervical cancer remains a leading cause of death among women of childbearing age despite the proven efficacy of screening in reducing mortality rates. Women…
Abstract Number: 0935 • ACR Convergence 2025
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Brianna Thompson², Vanessa Manada De Lobos² and Carla Marie Cuda³, ¹Northwestern University, Elmhurst, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (anxiety, cognitive dysfunction) lead to the devastating impact of this disease on patients’ health-related quality-of-life. Dysbiosis of gut microbiota…
Abstract Number: 0668 • ACR Convergence 2025
Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus
Takeshi Suzuki, Yoshiki Ishizaki, Takayasu Ando, Shotaro Suzuki, Keiichi Sakurai, Kumiko Tonooka, Yukiko Takakuwa, Hiroko Nagafuchi, Seido Ooka and Kimito Kawahata, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Background/Purpose: While both metformin (MET) and SGLT2 inhibitors (SGLT2i) have potential immunomodulatory effects in Systemic Lupus Erythematosus (SLE), their comparative efficacy in glucocorticoid (GC)-sparing remains…
Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Paola Vidal Montal¹, Javier Narváez², Aina Fabregat³, Iñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Andrea Hernández-martín⁶, Clara Moriano⁷, Maria Garcia-Villanueva⁸, Sandra Garrote Corral⁹, Sergi Heredia¹⁰, Julia Martínez Barrio¹¹, Júlia Bernardez Moreno¹², Paloma Vela Casasempere¹³, Beatriz Tejera Segura¹⁴, Leyre Riancho¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Maria Piqueras García¹⁸, Beatriz Frade Sosa¹⁹, José Gomez-Puerta²⁰, Consuelo Ramos Giraldez²¹, Tarek Salman Montes²², María Galindo-Izquierdo²³, EVA GLORIA TOMERO MURIEL²⁴, Jaime calvo²⁵, Jorge Juan Fragío Gil²⁶, Marta De la Rubia Navarro²⁷, Berta Magallares²⁸ and Irene Altabás-González²⁹, ¹Bellvitge University Hospital, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁵Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁶Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁷Hospital León, LEON, Castilla y Leon, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹Hospital Ramón y Cajal, Madrid, ¹⁰Hospital Moisès Broggi, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁴Hospital Insular de Gran Canaria, Las palmas, Spain, ¹⁵Hospital de Sierrallana, Torrelavega, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Servicio Murciano de Salud, Murcia, Spain, ¹⁹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ²²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²³Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁴Hospital Universitario de la Princesa, Madrid, Spain, ²⁵Hospital de Araba, Vitoria, Spain, ²⁶Hospital General Universitario, Valencia, Spain, ²⁷Hospital de La Fe, Valencia, ²⁸Hospital de Sant Pau, Bareclona, ²⁹Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
Abstract Number: 0622 • ACR Convergence 2025
Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
Malvika Gupta¹ and Chander Raman², ¹Mayo Clinic, Rochester MN, Rochester, MN, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Shrinking Lung Syndrome (SLS) is a rare pulmonary complication of systemic lupus erythematosus (SLE), characterized by unexplained dyspnea, pleuritic chest pain, loss of lung…

« Previous Page
1
…
4
5
6
7
8
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].